News and Insights
MediTrust Health Raises Over RMB2 Billion in Series C Financing Successfully: ESG Drives Value Creation
Shanghai MediTrust Health Technology Co., Ltd. (hereinafter referred to as “MediTrust”), a leading innovative healthcare services platform in China, announced a successful capital raising of over RMB2 billion (approximately US$308 million) in a Series C financing jointly led by Boyu Capital and Janchor Partners. Lily Asia Ventures, Lake Bleu Capital, Bank of China Group Investment, AIHC Capital, Everbright Limited, New Alliance Capital, CICC, and several other investors also joined this round. Additionally, MediTrust attracted commitments from many existing shareholders, including Shanghai Biopharmaceutical Investment Fund, Sinovation Ventures, China Renaissance, and Marathon Venture Partners.
MediTrust Health organized the “iCare Cares for Patients with Rare Diseases” launching ceremony at the Shanghai Grand Theatre.
In 2020, a wave of “Huiminbao” insurance plans were successively launched across China, marking 2020 as the inaugural year of “Huiminbao”.
A summit dialogue themed “Creating a smart future: Kickstarting the golden age of the medical industry” took place in Shanghai.
MediTrust Health Launches China’s First Breast Reconstruction Prosthetic Device Insurance with Up to 100 Percent Payouts.
MediTrust Health and AstraZeneca held a strategic partnership signing ceremony at the 2021 Taihu Bay Future Healthcare Conference.
MediTrust Health officially announced the completion of its series B funding exercise worth RMB 1 billion.